#1 Clinical Trials Search in Europe

Posaconazole

This article explores the use of posaconazole, an antifungal medication, in clinical trials for the prevention and treatment of invasive fungal infections. Posaconazole, also known by its brand name Noxafil, has been studied in various formulations including oral suspension, tablets, and intravenous solutions. The trials aim to evaluate its efficacy, safety, and pharmacokinetics in different patient populations at high risk for fungal infections.

Table of Contents

What is Posaconazole?

Posaconazole, also known by its brand name Noxafil[1], is an antifungal medication used to prevent and treat various fungal infections. It belongs to a class of drugs called azole antifungals[1]. Posaconazole is sometimes referred to by its research names SCH 56592 or MK-5592[2].

What Conditions Does Posaconazole Treat?

Posaconazole is used to treat or prevent several fungal infections, including:

  • Invasive Aspergillosis: A serious fungal infection that primarily affects the lungs but can spread to other organs[2].
  • Fungal infections in patients with weakened immune systems: This includes patients undergoing chemotherapy for leukemia or stem cell transplantation[3].
  • Onychomycosis: A fungal infection of the toenails, although this is not its primary use[1].
  • Chagas disease: While primarily an antiparasitic treatment, posaconazole has been studied for use in this condition[4].

How Does Posaconazole Work?

Posaconazole works by blocking the production of ergosterol, an essential component of fungal cell membranes. By disrupting the fungal cell membrane, posaconazole effectively stops the growth and spread of fungal infections[5].

Available Formulations

Posaconazole is available in several formulations to suit different patient needs:

  • Oral suspension: A liquid form that can be taken by mouth[1].
  • Tablets: A solid oral form that may be easier for some patients to take[2].
  • Intravenous (IV) infusion: A form that is given directly into the bloodstream, usually in hospital settings[2].

Dosage and Administration

The dosage of posaconazole varies depending on the formulation and the condition being treated. Some common dosing regimens include:

  • Oral suspension: Typically 200-400 mg taken 2-3 times daily with food[1].
  • Tablets: Usually 300 mg taken twice daily on the first day, then 300 mg once daily[2].
  • IV infusion: Often 300 mg twice daily on the first day, then 300 mg once daily, infused over 90 minutes[6].

It’s important to note that dosages may be adjusted based on individual patient factors and the specific condition being treated. Always follow your healthcare provider’s instructions.

Efficacy of Posaconazole

Clinical trials have shown posaconazole to be effective in preventing and treating various fungal infections. For example:

  • In patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy, posaconazole was effective in preventing invasive fungal infections[3].
  • Studies have shown promising results in treating onychomycosis (toenail fungal infections), with various dosing regimens showing different levels of effectiveness[1].
  • Research is ongoing to evaluate posaconazole’s effectiveness in treating Chagas disease, a parasitic infection[4].

Potential Side Effects

Like all medications, posaconazole can cause side effects. Common side effects may include:

  • Nausea or vomiting
  • Diarrhea
  • Headache
  • Abdominal pain
  • Fever

More serious side effects, though rare, can occur. These may include liver problems or heart rhythm changes. It’s important to report any unusual symptoms to your healthcare provider[2].

Special Considerations

Several factors can affect how posaconazole works in your body:

  • Food intake: The oral suspension form of posaconazole should be taken with food or a nutritional supplement to improve absorption[5].
  • Mucositis: This condition, which involves inflammation of the digestive tract lining, may affect the absorption of oral posaconazole. In such cases, the IV form might be preferred[6].
  • Inflammation: Research is ongoing to understand how inflammation in the body might affect posaconazole levels[7].
  • Drug interactions: Posaconazole can interact with other medications. Always inform your healthcare provider about all medications you’re taking[3].
Aspect Details
Drug Formulations Oral suspension, tablets, intravenous solution
Primary Uses Prevention and treatment of invasive fungal infections
Target Populations Patients with acute myeloid leukemia, myelodysplastic syndrome, stem cell transplant recipients, those with graft-versus-host disease
Dosing Regimens Varied across trials, e.g., 100-400 mg daily for 12-24 weeks
Efficacy Measures Complete cure, effective treatment, treatment success rates
Safety Assessments Adverse events, laboratory values, vital signs
Pharmacokinetic Parameters Plasma concentration, AUC, Cmax, Cmin, Tmax, clearance
Special Considerations Impact of mucositis on absorption, comparison with other antifungals (e.g., terbinafine)

FAQ

  • What is posaconazole used for in clinical trials? Posaconazole is primarily used in clinical trials for the prevention and treatment of invasive fungal infections, particularly in patients with compromised immune systems such as those undergoing chemotherapy for leukemia or stem cell transplantation.
  • What formulations of posaconazole are being studied? Clinical trials are investigating various formulations of posaconazole, including oral suspensions, tablets, and intravenous (IV) solutions. These different forms allow for flexibility in administration based on patient needs and conditions.
  • How is the effectiveness of posaconazole measured in trials? The effectiveness of posaconazole is often measured by evaluating complete cure rates, effective treatment rates, and treatment success rates for fungal infections. Researchers also monitor the drug's concentration in the blood to ensure it reaches therapeutic levels.
  • What are some common side effects observed in posaconazole trials? While specific side effects are not detailed in the provided information, clinical trials typically monitor for adverse events, changes in laboratory values, and vital signs. The safety profile of posaconazole is an important aspect of these studies.
  • How long do posaconazole clinical trials typically last? The duration of posaconazole clinical trials varies, but many studies evaluate patients for several weeks to months. For example, some trials measure outcomes at 48 weeks, while others focus on shorter periods like 10-28 days for pharmacokinetic assessments.

Ongoing Clinical Trials on Posaconazole

  • Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +2

  • Study of Posaconazole for Preventing Fungal Infections in Patients Receiving Stem Cell Transplants for Blood Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of BGB-11417 and Azacitidine for Patients with Myeloid Malignancies (AML, MDS, MDS/MPN)

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Methylprednisolone and Methoxsalen for Treating Grade II Acute Graft-Versus-Host Disease in Adult Stem Cell Transplant Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Posaconazole for Treating Fungal Infections in Children Under 2 Years

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Greece Poland

  • Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Posaconazole and Fluconazole for Preventing Fungal Infections in Patients with Acute Myeloid Leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France

  • Study on S65487 and Azacitidine for Adults with Untreated Acute Myeloid Leukemia Not Suitable for Intensive Treatment

    Not recruiting

    1 1 1
    Investigated drugs:
    France Spain

  • Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. In posaconazole trials, PK studies help determine the optimal dosing and administration methods.
  • Invasive Fungal Infection (IFI): A serious infection caused by fungi that can spread throughout the body, often affecting people with weakened immune systems. Posaconazole is studied for its ability to prevent and treat these infections.
  • Onychomycosis: A fungal infection of the nails, typically affecting toenails. Some posaconazole trials have focused on treating this condition.
  • Neutropenic: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections. Neutropenic patients are often included in posaconazole trials due to their high risk of fungal infections.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, used in pharmacokinetic studies to assess how much of the drug is available in the body.
  • Trough Concentration: The lowest concentration of a drug in the blood, typically measured just before the next dose is administered. This helps ensure that posaconazole levels remain therapeutic between doses.
  • Mucositis: Inflammation and ulceration of the mucous membranes lining the digestive tract, often a side effect of chemotherapy. Some trials study how mucositis affects posaconazole absorption.
  • Steady State: The condition where the overall intake of a drug is in dynamic equilibrium with its elimination, typically reached after multiple doses. Posaconazole trials often measure drug concentrations at steady state.

References

  1. https://clinicaltrials.gov/study/NCT00491764
  2. https://clinicaltrials.gov/study/NCT04218851
  3. https://clinicaltrials.gov/study/NCT01200355
  4. https://clinicaltrials.gov/study/NCT01162967
  5. https://clinicaltrials.gov/study/NCT00936117
  6. https://clinicaltrials.gov/study/NCT02805946
  7. https://clinicaltrials.gov/study/NCT02492802